330 related articles for article (PubMed ID: 31964786)
1. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Romero JM; Grünwald B; Jang GH; Bavi PP; Jhaveri A; Masoomian M; Fischer SE; Zhang A; Denroche RE; Lungu IM; De Luca A; Bartlett JMS; Xu J; Li N; Dhaliwal S; Liang SB; Chadwick D; Vyas F; Bronsert P; Khokha R; McGaha TL; Notta F; Ohashi PS; Done SJ; O'Kane GM; Wilson JM; Knox JJ; Connor A; Wang Y; Zogopoulos G; Gallinger S
Clin Cancer Res; 2020 Apr; 26(8):1997-2010. PubMed ID: 31964786
[TBL] [Abstract][Full Text] [Related]
2. Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer.
Xu JL
Dig Dis Sci; 2023 Mar; 68(3):831-840. PubMed ID: 35859262
[TBL] [Abstract][Full Text] [Related]
3. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
[TBL] [Abstract][Full Text] [Related]
4. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
5. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
8. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma.
Cannon A; Thompson CM; Maurer HC; Atri P; Bhatia R; West S; Ghersi D; Olive KP; Kumar S; Batra SK
Clin Cancer Res; 2020 Nov; 26(22):6051-6063. PubMed ID: 32873571
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
12. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
[TBL] [Abstract][Full Text] [Related]
13. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.
Hirth M; Gandla J; Höper C; Gaida MM; Agarwal N; Simonetti M; Demir A; Xie Y; Weiss C; Michalski CW; Hackert T; Ebert MP; Kuner R
Gastroenterology; 2020 Aug; 159(2):665-681.e13. PubMed ID: 32330476
[TBL] [Abstract][Full Text] [Related]
14. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models.
Torphy RJ; Sun Y; Lin R; Caffrey-Carr A; Fujiwara Y; Ho F; Miller EN; McCarter MD; Lyons TR; Schulick RD; Kedl RM; Zhu Y
Nat Commun; 2022 Jan; 13(1):97. PubMed ID: 35013216
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
16. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
17. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma.
Qian L; Yu S; Yin C; Zhu B; Chen Z; Meng Z; Wang P
Pancreatology; 2019 Mar; 19(2):340-345. PubMed ID: 30685120
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
[TBL] [Abstract][Full Text] [Related]
20. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.
Chew V; Chen J; Lee D; Loh E; Lee J; Lim KH; Weber A; Slankamenac K; Poon RT; Yang H; Ooi LL; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
Gut; 2012 Mar; 61(3):427-38. PubMed ID: 21930732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
